How the WHO Pandemic Agreement's Pathogen Access System Rewires Global Vaccine Sharing

The popular narrative surrounding the World Health Organization’s Pandemic Agreement, adopted in May 2025, is that the world finally has a binding treaty to prevent the vaccine hoarding seen during COVID-19. The reality is far more complicated. The treaty itself is largely a framework; the actual engine designed to force equitable distribution is a mechanism called the Pathogen Access and Benefit-Sharing (PABS) system. Right now, PABS is essentially an empty annex. While diplomats celebrate the overarching agreement, the legally binding terms that will dictate how pharmaceutical companies access pandemic-potential viruses—and what they must give back in return—are still being fiercely negotiated in Geneva.[1][4]

To understand PABS, you have to understand the fundamental trade-off it attempts to codify. During the early days of COVID-19, scientists in the Global South rapidly shared the genomic sequences of the novel coronavirus and its subsequent variants, such as Omicron. This data allowed Western pharmaceutical companies to design mRNA vaccines in record time. However, the countries that provided the data were often pushed to the back of the line when it came to purchasing the resulting vaccines, or were hit with immediate travel bans.

PABS is designed to fix this "science-for-science" inequity by linking access to biological materials directly to benefit-sharing. Under Article 12 of the Pandemic Agreement, countries commit to rapidly sharing physical pathogen samples and their genetic sequence data through WHO-coordinated laboratory networks. In exchange, the system mandates that any manufacturer using this data to develop vaccines, therapeutics, or diagnostics (VTDs) must sign a legally binding contract to share the resulting products.[1][2]

The most concrete mechanism proposed within PABS is the "20% rule." If a manufacturer utilizes the WHO network to access a pathogen with pandemic potential, they are obligated to provide 20% of their real-time production of any resulting medical countermeasures to the WHO during a declared public health emergency. Half of this allocation—10% of total production—must be donated outright as a charitable contribution. The remaining 10% must be offered to the WHO at affordable, non-profit prices for distribution to low- and middle-income countries based on public health needs rather than purchasing power.[2][3]

While the 20% quota sounds like a straightforward regulatory tax, implementing it requires tracking a highly intangible asset: Digital Sequence Information (DSI). Modern vaccine development rarely requires physical vials of a virus to be shipped across borders. Instead, researchers download the genetic code of a pathogen from open-source databases. The challenge for PABS is how to enforce a binding contract on a pharmaceutical company that simply downloads a sequence from the internet.[2]

This enforcement gap has triggered a massive geopolitical standoff over the architecture of the PABS databases. A coalition of African nations, alongside other developing economies, is pushing for a "Federated Model." In this system, sovereign nations retain control over their pathogen data through regional nodes. Before a researcher or manufacturer can access the sequence, they must register with a central catalogue and sign a Data Access Agreement (DAA) that legally binds them to the 20% benefit-sharing quota. The data stays at the sovereign node, and only the analytical results leave.

Conversely, the European Union and several developed nations with large pharmaceutical sectors are advocating for a "Hybrid Model." This approach proposes a mix of mandatory and voluntary measures. It would maintain a global WHO-controlled PABS system with benefit-sharing commitments, but it would also allow countries to share pathogen material outside the formal system on mutually agreed terms. Critics argue this hybrid approach creates a massive loophole, allowing companies to access sequence data anonymously without triggering the mandatory 20% donation requirement.

The pharmaceutical industry has expressed deep skepticism about the operational realities of PABS. Industry groups argue that mandatory set-asides could disrupt complex supply chains and disincentivize rapid research and development during a crisis. If accessing WHO data comes with heavy legal and financial liabilities, some companies might choose to wait for data to emerge through alternative channels, potentially delaying the development of life-saving countermeasures.[3]

Furthermore, the scope of what constitutes a "pathogen with pandemic potential" remains hotly debated. Draft appendices have included viruses like Ebola, Zika, and SARS-like respiratory diseases, but the exact list will determine which research triggers PABS obligations. If the net is cast too wide, routine research into endemic diseases could become entangled in complex international benefit-sharing contracts, slowing down everyday scientific collaboration.[3]

The jurisdictional overlap with other international treaties adds another layer of legal uncertainty. The Convention on Biological Diversity (CBD) and its Nagoya Protocol already govern the equitable sharing of genetic resources, but they operate on a bilateral basis and often involve monetary compensation. PABS is attempting to carve out a specialized, multilateral system focused exclusively on pandemic pathogens, prioritizing in-kind contributions (vaccines and therapeutics) over cash. Reconciling these two frameworks without creating contradictory legal obligations for researchers is a monumental task.[2]

Ultimately, the success of the WHO Pandemic Agreement hinges entirely on the finalization of the PABS annex. Without it, the broader treaty cannot be fully ratified or enter into force. Negotiators are racing against a ticking clock, with the Intergovernmental Working Group (IGWG) holding critical meetings throughout late 2026 to bridge the gap between the federated and hybrid models.[1]

The stakes are immense. If a robust PABS system is implemented, it will fundamentally rewire the global pharmaceutical market, shifting it from a purely market-driven scramble to a system with a guaranteed baseline of equity. If the negotiations fail, or if the resulting system is riddled with loopholes, the next pandemic will likely mirror the last: a triumph of rapid scientific innovation, followed by a catastrophic failure of global distribution.[4]